Holen Sie sich die Stockscreener-App
88.98
1.98%
1.73
Schlusskurs vom Vortag:
$87.25
Offen:
$86.45
24-Stunden-Volumen:
776.15K
Relative Volume:
0.64
Marktkapitalisierung:
$7.85B
Einnahmen:
$688.00K
Nettoeinkommen (Verlust:
$-168.74M
KGV:
-37.74
EPS:
-2.3577
Netto-Cashflow:
$-185.87M
1W Leistung:
-1.53%
1M Leistung:
-15.21%
6M Leistung:
+117.02%
1J Leistung:
+423.72%
1-Tages-Spanne:
$84.68
$89.18
1-Wochen-Bereich:
$84.00
$90.97
52-Wochen-Spanne:
$14.51
$110.17
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
88.98 | 9.50B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-12-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-26 | Eingeleitet | Deutsche Bank | Buy |
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
RTW Investments, LP Expands Spyre Therapeutics (SYRE) Stake With Strategic Add - GuruFocus
Is Spyre Therapeutics (SYRE) Fully Priced After Its SPY772 Program And SKYLIGHT Trial Launch? - simplywall.st
This Stock’s Already Up Nearly 600% Over the Past Year - Yahoo Finance
Price to book forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE - TradingView
Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week HighHere's What Happened - MarketBeat
Spyre Therapeutics stock hits 52-week high at 108.16 USD - Investing.com
Spyre Therapeutics (SYRE) Edges Higher at $104.60: Consolidation Builds Ahead of Resistance TestCall Wall - Vinanet
Handelsbanken Fonder AB Makes New $2.31 Million Investment in Spyre Therapeutics, Inc. $SYRE - MarketBeat
Wall Street Zen Downgrades Spyre Therapeutics (NASDAQ:SYRE) to Sell - MarketBeat
Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $123 - Moomoo
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $129 - Moomoo
Perceptive Advisors discloses 4.9% stake in Spyre Therapeutics (SYRE) via Master Fund - Stock Titan
RTW Investments (SYRE) reports 4.8% Spyre Therapeutics stake for managed funds - Stock Titan
Dimensional Fund Advisors LP Sells 29,593 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics, Inc. Stock 12‑Month Price Target Raised to $126.85, Implies 22% Upside - TradingView
Spyre Therapeutics (SYRE) Pulls Back 2.46% as Bulls Defend $97.6 SupportVol Target Rebalance - Vinanet
Price to earnings forward of Spyre Therapeutics, Inc – SWB:3920 - TradingView
Price to book forward of Spyre Therapeutics, Inc – SWB:3920 - TradingView
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
SYRE Maintained by BTIG -- Price Target Raised to $132.00 - GuruFocus
Spyre Therapeutics director Jeffrey W. Albers disposes of USD 2.39 million in common shares - Bitget
Spyre Therapeutics, Inc. $SYRE Shares Bought by Bank of America Corp DE - MarketBeat
Spyre Therapeutics Insider Sold Shares Worth $2,404,190, According to a Recent SEC Filing - marketscreener.com
Spyre Therapeutics director Albers sells $2.4m in stock By Investing.com - Investing.com India
Spyre Therapeutics director Albers sells $2.4m in stock - Investing.com India
Spyre Therapeutics (NASDAQ:SYRE) Director Sells 18,000 Shares - MarketBeat
Spyre Therapeutics (SYRE) director logs 5,000-share option exercise and 23,000-share sale - Stock Titan
Spyre Therapeutics Launches Program, Mid-Stage Trial for Drug Combination to Treat Hidradenitis Suppurativa - marketscreener.com
Spyre Therapeutics Announces Launch Of Spy772 Program - TradingView
Spyre Therapeutics launches combination therapy trial for hidradenitis suppurativa - Investing.com
Spyre Therapeutics launches combination therapy trial for hidradenitis suppurativa By Investing.com - Investing.com Nigeria
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa - The Manila Times
Spyre Therapeutics, Inc. Launches SPY772 Program And Initiates Phase 2 SKYLIGHT Trial In Hidradenitis Suppurativa - marketscreener.com
California State Teachers Retirement System Purchases 11,204 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat
Can Spyre Therapeutics (SYRE) Justify Its Premium After Positive Phase 2 Data? - Yahoo Finance
Price to sales forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE - TradingView
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $128 - Moomoo
Spyre Therapeutics (NASDAQ:SYRE) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Spyre Therapeutics, Inc. SEC Filing (Aug 7, 2026) - Stock Titan
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics, Inc. (SYRE) Investor Outlook: Promising Biotech with 4.98% Upside Potential - directorstalkinterviews.com
Price to earnings forward of Spyre Therapeutics, Inc – DUS:3920 - TradingView
Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know - The Motley Fool
A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know - The Motley Fool
SPYRE THERAPEUTICS INC : RAYMOND JAMES RAISES TARGET PRICE TO $121 FROM $88 - webull.com
We Think Spyre Therapeutics (NASDAQ:SYRE) Can Easily Afford To Drive Business Growth - Moomoo
Cameron Turtle, Spyre Therapeutics CEO, sells $1.43m in stock By Investing.com - Investing.com South Africa
Spyre CFO Scott Burrows sells $716,771 in stock By Investing.com - Investing.com Nigeria
Form 4 Spyre Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spyre Therapeutics Inc-Aktie (SYRE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Albers Jeffrey W. | Director |
Aug 07 '26 |
Sale |
104.55 |
18,000 |
1,881,840 |
9,360 |
| Albers Jeffrey W. | Director |
Aug 07 '26 |
Sale |
104.47 |
5,000 |
522,350 |
0 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):